Navigation Links
Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
Date:9/5/2007

U.S. Biogeneric Agents to Reach $2 Billion in Sales by 2016, According to a

New Report from Decision Resources

WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen, the leading manufacturer of biologic agents with biologic sales of more than $14 billion in 2006, and Genentech, the second leading biologics manufacturer with biologic sales of more than $9 billion in 2006, are bracing themselves for heavy pressure from biogeneric manufacturers. According to the new special report entitled Biogenerics 2007- 2016: Physician and Payer Acceptance Fuels Brand Erosion, Amgen products such as Enbrel, Epogen and Neupogen will be eroded by biogeneric sales in both the United States and Europe. In fact, on August 31, 2007, European regulators approved Sandoz's biogeneric epoetin alfa for patients with renal anemia and those receiving chemotherapy. Genentech products such as Rituxan/MabThera and Herceptin represent windfall opportunities for biogeneric hopefuls.

The report also reveals that, with the launch of biogeneric TNF-alpha inhibitors in 2012, the U.S. biogeneric market will expand substantially through 2016 and reach a total of more than $2 billion in annual sales.

"This growth in the U.S. biogeneric market will be driven by biogeneric TNF-alpha inhibitors for rheumatoid arthritis, which we project will generate $700 million in sales by 2016, and will be supported by biogeneric versions of interferon-betas for multiple sclerosis, Herceptin for breast cancer, and ESPs for chemotherapy-induced anemia, each of which will post more than $250 million in 2016 U.S. sales," said Andrew Merseth, analyst at Decision Resources.

About Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion

Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion covers 13 key biologic
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genentechs Winning Streak
2. TeraMedica embraces open source project
3. Center for Technology Transfer embraces "Cleantech"
4. Wisconsin Film Festival embraces new online ticket ordering system
5. Wisconsin Historical Society Embraces New Web Site Technology
6. Chippewa Valley Embraces Nanotechnology
7. Wisconsin early-stage companies must position themselves to get capital
8. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
9. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
10. Cellular Dynamics hits market with UW research heavyweights
11. Governors Growth Council hopes to go light on paperwork and heavy on ideas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Alto, Calif. (PRWEB) November 20, 2014 ... a nonprofit, public policy research organization representing leading ... pharmaceutical firms, and PwC US today ... states in life sciences industry growth. The trend ... 2013. The 2015 California Biomedical Industry Report ...
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... September 30, 2014.  Biorem,s complete 2014 third quarter financial statements and ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , 2014 ... 5,281 , 6,715 , 14,476 Gross profit ...
(Date:11/18/2014)... CA (PRWEB) November 17, 2014 Athena Signature ... Salk , Dr. Beverly Emerson, a professor in the Regulatory ... genes. Her most recent discovery points to an “off switch” ... Emerson’s career and how her local research is making a ... present her findings and then join host Cheryl K. Goodman, ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... escalation portion of its U.K. clinical trial ... of REOLYSIN(R) in,combination with paclitaxel and carboplatin ... neck, melanoma, lung and ovarian., "The ...
... (eRT), (Nasdaq: ERES ), and nSpire ... integrated Cardiac Safety and Pulmonary Core Lab,Services ... a leading provider of centralized,electrocardiographic (ECG), eClinical ... biotechnology, medical device, and related,industries. nSpire Health ...
... Capacity of Menstrual Stem Cells, OLDSMAR, Fla., ... of a study published this month,in Cell Transplantation ... rapidly and have significant potential to develop into ... accessible,non-controversial and renewable stem cell source, and these ...
Cached Biology Technology:Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial 2Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial 3eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 2eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 3Stem Cells From Menstrual Blood Show Therapeutic Potential 2Stem Cells From Menstrual Blood Show Therapeutic Potential 3Stem Cells From Menstrual Blood Show Therapeutic Potential 4Stem Cells From Menstrual Blood Show Therapeutic Potential 5
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/10/2014)... pods began appearing on U.S. store shelves in early ... ever since. The small packets can be tossed into ... a liquid or powder. The convenience, though, has come ... from researchers at Nationwide Children,s Hospital found that from ... of 17,230 children younger than 6 years of age ...
(Date:11/6/2014)... occur because of metastasis, yet progress in preventing ... , "It,s been particularly challenging to design drugs ... fellow in systems biology at Harvard Medical School. ... after they,ve already metastasized." , Gujral and colleagues ... help researchers better understand how metastasis begins. Their ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3
... two decades, the laboratory mouse has been the workhorse of ... effectively and reliably manipulate to study human diseases and conditions. ... added another experimental research animal to the scientific stable: the ... issue of Nature Methods, UT Southwestern researchers detail how they ...
... potentially doubling the output of the world,s fourth largest food ... at Cornell University, as well as the University of Goettingen ... major South American pest infests potato tubers, the plant produces ... write in the peer-reviewed journal Ecological Applications (April ...
... 27, 2010) The Rice University-led international journal ... week released a special free virtual edition that ... the Exxon Valdez oil spill. It also provides ... science studies published over the publication,s 29-year history. ...
Cached Biology News:UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats 2UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats 3To double spud production, just add a little spit 2Leading journal makes Exxon Valdez and other oil-related studies available free 2Leading journal makes Exxon Valdez and other oil-related studies available free 3Leading journal makes Exxon Valdez and other oil-related studies available free 4Leading journal makes Exxon Valdez and other oil-related studies available free 5
... PCRx Enhancer System is used ... to optimize PCR of problematic ... PCRX Enhancer Solution with 10X ... primer specificity broader magnesium concentration ...
... Immunogen: Synthetic peptide derived from ... junctophilin-2. Specificity: Specific for the ... controls: mouse skeletal muscle homogenates frozen ... Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store at ...
Abin-2 (N-16)...
CLIM-2 (T-16)...
Biology Products: